Trial Profile
A Phase I Open-Label Study to Evaluate the Safety and Tolerability of Escalating Doses of DAVANAT (A Galactomannan Derivative) in the Presence and Absence of 5-Fluorouracil (5-FU) in Subjects With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 14 Mar 2012
Price :
$35
*
At a glance
- Drugs Galactomannan (Primary) ; Fluorouracil
- Indications Solid tumours
- Focus Adverse reactions
- 10 Jun 2011 New trial record